Kim Davenport
0009-0002-6117-2319
Arvinas (United States)
1 paper found
Refreshing results…
Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models
Missing publications? Search for publications with a matching author name.